Bayer's Critical Fortnight: A Quiet Period Before a Legal and Financial Storm

Bayer's AGM and a pivotal U.S. Supreme Court case on glyphosate litigation could reshape the company's financial risk and stock trajectory in a critical fortnight.

Investors in Bayer are bracing for a fortnight of high-stakes events, bookended by a shareholder meeting and a crucial court hearing. The German conglomerate has entered a mandatory quiet period, limiting official communication just as two pivotal dates approach. This silence precedes a week that could significantly reshape the company's risk profile and financial trajectory.

The immediate focus is the virtual Annual General Meeting on Friday, 24 April. Shareholders will vote on a proposed dividend of 0.11 euros per share, unchanged from the previous year, with the ex-date set for 27 April and payment following on 29 April. The agenda also includes personnel decisions for the Supervisory Board, with Marcel Smits, former Chairman and CEO for Cargill's Asia-Pacific region, and Alfred Stern standing as candidates. Management has signaled a continued focus on debt reduction, prioritizing the use of retained earnings to tackle the company's substantial leverage.

Just three days later, on Monday, 27 April, the U.S. Supreme Court will hear arguments in the pivotal Durnell case. A favorable ruling could dramatically reduce the unpredictable financial risks associated with ongoing glyphosate litigation. For Bayer's management, this would translate into more calculable provisions and the alleviation of one of the group's most persistent overhangs. The market impact of a positive decision could be substantial, potentially bringing the stock's old yearly high near 49 euros back into view.

The stock has already shown resilience, closing at 41.36 euros on Monday and marking a gain of nearly nine percent since the start of the year. While this represents progress, the share price remains approximately 16 percent below its 52-week high of 49.17 euros. The fundamental picture is mixed. For the full year 2025, Bayer reported currency-adjusted sales growth of 1.1 percent to approximately 45.6 billion euros and successfully reduced its net financial debt by 8.5 percent to just under 30 billion euros. However, a negative EBIT of over one billion euros and a nearly one-third collapse in free cash flow to around 2.1 billion euros, driven by over 6 billion euros in litigation-related special charges, painted a challenging picture.

Looking ahead, the company forecasts 2026 sales between 45 and 47 billion euros, with EBITDA before special items expected in a range of 9.6 to 10.1 billion euros. Analysts anticipate an adjusted earnings per share of at least 4.30 euros for the full year. Yet, Bayer plans for a negative free cash flow of around 5 billion euros in 2026, primarily due to anticipated glyphosate settlement payments.

Amid these financial and legal crosscurrents, external assessments offer a glimmer of optimism. Goldman Sachs analyst James Quigley recently raised his price target on the pharmaceutical stock from 54 to 55 euros, maintaining a buy rating. He anticipates a strong first quarter, with figures due on 12 May likely to exceed current market expectations. Furthermore, sustainability ratings have improved, with MSCI Solutions granting Bayer its first AA sustainability rating and Sustainalytics removing its "Red Flag" status in late 2025, citing progress in mitigating glyphosat risk.

The coming days will provide concrete answers where speculation has reigned. The outcomes of the shareholder vote and, more critically, the Supreme Court hearing will deliver hard facts that could either unlock value or reaffirm the challenging path ahead for the Leverkusen-based giant.